Iwase Cosfa Co.,Ltd. serves as the exclusive Japanese agent for contracted clinical safety studies.
This page introduces the key features of Iwase Cosfa Co.,Ltd.’s non-clinical testing services, examples of pathological models, and case studies.
We hope you can use this information as a reference when selecting an CRO for you non-clinical needs.
Iwase Cosfa Co.,Ltd. conducts safety evaluations across a broad range of industries, including cosmetics, quasi-drugs, food, chemicals, agriculture chemicals, and pharmaceuticals. They offer many testing such as acute toxicity (single-dose/oral and dermal), genotoxicity (Ames/chromosomal aberration), skin irritation (patch test/cumulative irritation), and environmental toxicity (aquatic life impact assessment). Through their partnership with BIOTOXTECH in South Korea, the company has established a GLP-compliant testing platform for international standards (FDA/ICH), providing end-to-end safety evaluation from raw material screening to pre-market assessment. Iwase Cosfa Co.,Ltd. also focuses on alternative methods to animal testing, particularly in line with the EU Cosmetics Directive, offering strong regulatory adaptability.
Specializing in dermatological assessments, the company conducts tests such as collagen and hyaluronic acid production, anti-wrinkle efficacy (56-day human clinical trial), whitening (melanin suppression), and hair tensile strength. Its proprietary “Wrinkle Reset” formulation has demonstrated anti-wrinkle effects in both non-clinical studies (fibroblast activation) and human trials (improvement of facial sagging in 40 subjects). This enables packaged service proposals covering everything from formulation design to efficacy data acquisition. In non-comedogenic testing, acne formation risk is statistically evaluated using the occlusive patch method with Finn Chambers.
As the exclusive Japanese representative for BIOTOXTECH, Iwase Cosfa Co.,Ltd. offers integrated services from study designing to data management at GLP-certified facilities. Through their joint research with Kyoto University’s Virus Research Institute, the company has developed a virus inactivation verification method applied to biological safety assurance of raw materials. In addition to their ISO9001 and ISO13485-compliant quality management systems, they also have expertise in preparing application materials for PMDA and EU regulatory authorities. They have set up more strict study protocols for subject selection criteria (differences in sensory irritation scores between positive/negative control substances) and evaluation timing (immediate, 2.5 minutes, and 5 minutes post-application), ensuring high reproducibility and reliability.
A South Korea-based company who provides safety evaluation services for pharmaceuticals, foods, cosmetics, chemicals, and agrochemicals. BIOTOXTECH supports pharmaceutical and agrochemical regulatory submissions as well as exploratory and screening studies for internal research.
Iwase Cosfa Co.,Ltd. evaluates the efficacy of raw materials and products towards humans and effects on environment. Applicable to quasi-drugs, food-related products, chemicals, and consumer goods, the company offers acute toxicity, genotoxicity, irritation, sensitization, patch, repeated-dose toxicity, and environmental toxicity tests.
They offer efficacy studies for ingredients in raw materials and finished products. Areas of focus include skin aging, whitening, allergy, and hair care. Test types include collagen and hyaluronic acid production, cell activation, skin moisturization, anti-wrinkle, whitening, inflammatory response suppression, alkaline phosphatase (ALP) activity, hair papilla cell activation, hair growth, hair moisture content, and hair tensile strength tests.
Partnered with BIOTOXTECH in Korea, Iwase Cosfa Co.,Ltd. serves as the exclusive Japanese agent for contracted clinical safety studies.
| Address | 1-7-11 Doshomachi, Chuo-ku, Osaka-shi, Osaka |
|---|---|
| Tel | 06-6231-3456 |
| Website | https://www.cosfa.co.jp/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.